-+ 0.00%
-+ 0.00%
-+ 0.00%

Axsome Therapeutics surged 23.3% at the end of Wednesday, after the company's Alzheimer's treatment received priority review from the FDA.

Zhitongcaijing·12/31/2025 20:57:01
Listen to the news
Axsome Therapeutics surged 23.3% at the end of Wednesday, after the company's Alzheimer's treatment received priority review from the FDA.